Pfizer
Pfizer delays vaccine deliveries to 8 EU nations: Spain
The Spanish branch of Pfizer informed Madrid on Sunday night of the delay in shipments to the eight nations due to a 'problem in the loading and shipment...
-
US drug regulator denies inteference over Pfizer vaccine
The FDA issued an emergency use authorization for the two-dose regimen late on Friday night following reports President Donald Trump had threatened to fire the head of the agency if he didn't act that day.
-
US considers Pfizer COVID-19 vaccine approval
Pfizer scientist Kathrin Jansen told the panel this was a result of the innovative messenger RNA technology behind the vaccine, an approach that has never before been approved.
-
Israel gets first delivery of Pfizer COVID-19 vaccine
The shipment was the first of eight million doses ordered from US pharmaceutical giant Pfizer BioNTech.
-
Pfizer chief insists no corners cut on vaccine testing
As Britain on Tuesday became the first Western country to start a mass coronavirus vaccine campaign, using the new Pfizer-BioNTech jab, Bourla said people should feel confident that it is safe and effective.
-
US expert committee upbeat on Pfizer COVID-19 vaccine
An independent committee advising the FDA will meet Thursday on the matter, after Britain became the first country to greenlight the vaccine last week.
-
UK approves Pfizer-BioNTech COVID-19 vaccine
The United Kingdom has given pharmaceutical company Pfizer emergency authorisation to introduce its coronavirus vaccine with the aim to start roll out next week. #Covid19 #vaccinne
-
UK approves Pfizer-BioNTech vaccine for rollout from 'next week'
After months of 'rigorous' clinical trials and thorough analysis of the data, the MHRA 'concluded that the vaccine has met its strict standards of safety, quality and effectiveness', the statement added.
-
BioNTech/Pfizer file for EU approval of COVID-19 vaccine
The two companies said they had submitted an application to the European Medicines Agency (EMA) on Monday seeking "Conditional Marketing Authorisation (CMA)" for their vaccine.
-
The COVID-19 vaccine: 'SA is at the bottom of the queue'
The recent success of vaccine trials has provided some global hope of beating COVID-19. But when will South Africans be able to get their hands on it? We spoke to the country's top scientists to find.
-
Pfizer/BioNTech to seek emergency use approval for coronavirus vaccine
The companies this week announced that a completed study of trials of the product showed it was 95% effective in protecting people from coronavirus infection.
-
ANALYSIS: Moderna follows Pfizer with good vaccine news – what does this mean?
Many more vaccine trial results are likely to follow in the coming months, so it’s necessary to dig deeper to find out exactly what any new results mean.
-
ANALYSIS: Pfizer COVID vaccine: promising results. What needs to happen next?
The results from the Pfizer/BioNTech COVID-19 vaccine trial are promising, but there’s a lot more we now need to confirm.
-
Biden: Vaccine news gives 'hope,' but long battle ahead
Pfizer and BioNTech said that according to preliminary findings, protection in patients was achieved seven days after the second of two doses, and 28 days after the first.
-
Pfizer says COVID-19 vaccine 90% effective in Phase 3 trial
According to preliminary findings, protection in patients was achieved seven days after the second of two doses, and 28 days after the first.
-
Pfizer to charge other developed countries on par with US for vaccine deals
Pfizer executives said they expect people will need to receive continued vaccinations for a number of years to maintain herd immunity globally, either because immunity may diminish over time or the virus will mutate.
-
Moderna, Pfizer start decisive COVID-19 vaccine trials, eye year-end launches
The trials, both announced on Monday, are the first late-stage studies supported by the Trump administration’s effort to speed development of measures against the novel coronavirus.
-
Pfizer ends research for new Alzheimer's, Parkinson's drugs
Pfizer has invested heavily in research for Parkinson’s and Alzheimer‘s, and is one of several drugmakers, along with GlaxoSmithKline and Eli Lilly, that is part of the Dementia Discovery Fund.
-
GSK and Gilead go head to head as HIV drugs enter new phase
The stakes are high for the two leaders in the $27-billion-a-year HIV market, with shares of around 53 and 22% respectively, according to industry data.
